Purpose: The effect of a required preprinted order form on the prescribing of epoetin alfa was evaluated.
Summary: An initial drug-use evaluation (DUE) was conducted in January 2004 to determine how closely prescribing guidelines for epoetin alfa were being followed. A preprinted order form was then developed and approved by the medical staff, with use required for all adult epoetin alfa orders. A follow-up DUE was conducted in January 2006 to assess the effects of the preprinted order form on prescribing patterns. Expenditures for epoetin alfa for 12 months before and after implementation of the preprinted order form were also calculated. Data for 45 and 44 patients were reviewed for the initial and follow-up DUEs, respectively. Smaller doses were ordered at more frequent intervals and epoetin alfa was prescribed more often by nephrologists and less frequently by surgeons and critical care intensivists after implementation of the preprinted order form. Use of epoetin alfa according to hospital guidelines improved from 44% to 73% (p = 0.0089). Significantly more patients' ferritin and transferrin saturation values were measured postimplementation of the order form (p = 0.0176). In addition, the annual expense for epoetin alfa was reduced by $151,042, a 36% reduction from baseline.
Conclusion: Implementation of a required preprinted order form increased the frequency of appropriate prescribing of epoetin alfa in a community teaching hospital.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2146/ajhp060277 | DOI Listing |
Cureus
October 2024
Haematology, Norfolk and Norwich University Hospital, Norwich, GBR.
Background Myelodysplastic syndromes (MDS) are clonal myeloid disorders characterised by ineffective haematopoiesis, leading to anaemia that often requires dependence on red blood cell (RBC) transfusions. Epoetin alfa (Eprex®) is now a mainstay in the management of symptomatic anaemia in low-risk MDS patients, reducing transfusion dependence and improving the quality of life in this patient group. Objective This retrospective study aimed to assess the efficacy of epoetin alfa in treating symptomatic anaemia in low-risk MDS patients, focusing on transfusion independence and its relationship with baseline erythropoietin (EPO) levels and haemoglobin (Hb) response.
View Article and Find Full Text PDFFront Oncol
October 2024
Center of Oncocytogenomics, Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czechia.
Background: Luspatercept, an inhibitor of the transforming growth factor beta (TGF-β) pathway, is a novel treatment for anemic patients with lower-risk myelodysplastic syndromes (MDS) with transfusion dependence (TD) who do not respond to erythropoiesis-stimulating agents (ESA) therapy or are not suitable candidates for this treatment. We present real-world experience with luspatercept therapy from two hematology centers in the Czech Republic.
Methods: By January 2024, 54 MDS patients (33 men, 21 women) with a median age of 74 years (range, 55-95) were treated with luspatercept ± ESA at two Charles University hematology centers in Prague and Hradec Králové.
World J Pediatr
November 2024
SAMRC Extramural Unit for Stem Cell Research and Therapy, Department of Immunology, Faculty of Health Sciences, Institute for Cellular and Molecular Medicine, University of Pretoria, Room 5-64, Level 5, Pathology Building, 15 Bophelo Road (Cnr. Steve Biko and Dr. Savage Streets), Prinshof Campus, Gezina, Pretoria, South Africa.
Background: Neonatal encephalopathy (NE) due to suspected hypoxic-ischemic encephalopathy (HIE), referred to as NESHIE, is a clinical diagnosis in late preterm and term newborns. It occurs as a result of impaired cerebral blood flow and oxygen delivery during the peripartum period and is used until other causes of NE have been discounted and HIE is confirmed. Therapeutic hypothermia (TH) is the only evidence-based and clinically approved treatment modality for HIE.
View Article and Find Full Text PDFMedicina (Kaunas)
July 2024
Department of Oncology-Palliative Care, "Sf. Luca" Chronic Diseases Hospital, 041915 Bucharest, Romania.
: Small-cell lung cancer (SCLC) is an aggressive form of cancer with a poor prognosis. The two-year survival rate is 8% of all cases. : We present the case of a male patient who was 50 years old at the time of diagnosis in May 2022.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!